NEW YORK, June 26 – French functional genomics company GenOdyssee has appointed Jean Maral, a former Chiron Biopharmaceuticals executive, to the position of vice president and senior director of preclinical and clinical affairs, the company said Tuesday.
In addition, Mark Hofer, an attorney with Brown Rudnick Freed and Gesmer in Boston, will join the company’s business development and marketing board.
Maral will join GenOdyssee, of Les Ulis, France, after six years as director of clinical and scientific affairs at Chiron Biopharmaceuticals Europe, where he managed the clinical and preclinical development of several pharmaceutical products. Prior to Chiron, Maral served as medical director at Amgen France.
Hofer most recently oversaw intellectual property, public offerings, venture capital, entrepreneurial companies, and mergers and acquisitions at Brown Rudnick Freed and Gesmer. He also served as senior vice president, general counsel, and chief patent counsel at Genzyme in Cambridge, Mass.
GenOdyssee, founded in 1999, has specialized in identifying SNPs linked to disease using Denaturing High Performance Liquid Chromatography (DHPLC) and capillary sequencing, and studying the proteins encoded by those SNPs for use as possible therapeutics.
“These two distinguished individuals will be instrumental in helping us further our goal of developing drugs by applying an integrated approach to genetic variability,” Jean-Louis Escary, the company’s founder, president and chief scientific officer, said in a statement.